Thiazolidinediones: An update

Lancet

Volumn 355, Issue 9208, 2000, Pages 1008-1010

  Schoonjans, Kristina ^a   Auwerx, Johan ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; CELL NUCLEUS RECEPTOR; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG RECEPTOR BINDING; GENE CONTROL; HOST RESISTANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0034681773     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)90002-3     Document Type: Review

References (34)

1. Desvergne B., Wahli W. Peroxisome proliferator-activity receptors. nuclear control of metabolism Endocrinol Rev. 20:1999;649-688.
2. Auwerx J. PPARγ, the ultimate thrifty gene. Diabetologia. 42:1999;1033-1049.
3. Vamecq J., Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 354:1999;141-148.
4. Nolte R.T., Wisely G.B., Westin S.et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor γ Nature. 395:1998;137-143.
5. Spiegelman B.M., Flier J.S. Adipogenesis and obesity. rounding out the big picture Cell. 87:1996;377-389.
6. Fajas L., Fruchart J.C., Auwerx J. Transcriptional control of adipogenesis. Curr Opin Cell Biol. 10:1998;165-173.
7. Ristow M., Muller-Wieland D., Pfeiffer A., Krone W., Kahn C.R. Obesity associated with mutation in a genetic regulator of adipocyte differentation. N Engl J Med. 339:1998;953-959.
8. Deeb S., Fajas L., Nemoto M., Laakso M., Fujimoto W., Auwerx J. A Pro 12 Ala substitution in the human peroxisome proliferator-activated receptor gamma2 is associated with decreased receptor activity, improved insulin sensitivity, and lowered body mass index. Nat Genet. 20:1998;284-287.
9. Barak Y., Nelson M.C., Ong E.S., et al P.P.A. Rgamma is recruited for placental, cardiac, and adipose tissue development. Mol Cell. 4:1999;585-595.
10. Kubota N., Terauchi Y., Miki H., et al P.P.A. Rgamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell. 4:1999;597-609.
11. Rosen E.D., Sarraf P., Troy A.E., et al P.P.A. Rgamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 4:1999;611-617.
12. Shimomura I., Hammer R.E., Richardson J.A.et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue. a model for congenital generalized lipodystrophy Genes Dev. 12:1998;3182-3194.
13. Moitra J., Mason M.M., Olive M.et al. Life without fat. a transgenic mouse Genes Devel. 12:1998;3168-3181.
14. Martin G., Schoonjans K., Lefebvre A., Staels B., Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein (FATP) and acyl CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem. 272:1997;28210-28217.
15. Oakes N.D., Camilleri S., Furler S.M., Chisholm D.J., Kraegen E.W. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue availability in the rat. Metabolism. 46:1997;935-942.
16. Schwartz S., Raskin P., Fonseca V., Graveline J.F. Effect of troglitazone in insulin-treated patients with type II diabetes. N Engl J Med. 338:1998;861-866.
17. Suter S.L., Nolan J.J., Wallace P., Gumbiner B., Olefsky J.M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:1992;193-203.
18. Inzucchi S.E., Maggs D.G., Spollett G.R.et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes. N Engl J Med. 338:1998;867-872.
19. Plosker G.L., Faulds D. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs. 57:1999;409-438.
20. Balfour J.A., Plosker G.L. Rosiglitazone. Drugs. 57:1999;921-930. discussion 931-32.
21. Watkins P.B., Whitcomb R.W. Hepatic dysfunction associated wtih troglitazone. N Engl J Med. 338:1998;916-917.
22. Shibuya A., Watanabe M., Fujita Y.et al. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care. 21:1998;2140-2143.
23. Freid J., Everitt D., Boscla J. Rosiglitazone and hepatic failure. Ann Intern Med. 132:2000;164.
24. Al-Salman J., Arjomand H., Kemp D.G., Mittal M. Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med. 132:2000;121-124.
25. Min/+ mice. Nat Med. 4:1998;1053-1057.
26. Saez E., Tontonoz P., Nelson M.C.et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med. 4:1998;1058-1061.
27. Murakami K., Tobe K., Ide T., et al A. novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor α and γ effect of PPARα activation on normal lipid metabolism in liver of Zucker fatty rats Diabetes. 47:1998;1841-1847.
28. Shibata T., Matsui K., Nagao K., Shinkai H., Yonemori F., Wakitani K. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 364:1999;211-219.
29. Pill J., Kuhnle H.F. BM 17.0744: a structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity. Metabolism. 48:1999;34-40.
30. Willson T.M., Cobb J.E., Cowan D.J.et al. The structure activity relationship between peroxisome proliferator activated receptor γ antagonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 39:1996;665-668.
31. Berger J., Bailey P., Biswas C.et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ binding and activation correlate with antidiabetic actions in db/DB mice Endocrinology. 137:1996;4189-4195.
32. Kimura K.D., Tissenbaum H.A., Liu Y., Ruvkun G. Daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science. 277:1997;942-946.
33. Bohni R., Riesgo-Escovar J., Oldham S.et al. Autonomous control of cell and organ size by CHICO, a drosophila homolog of vertebrate IRS1-4. Cell. 97:1999;865-875.
34. Lee C.K., Klopp R.G., Weindruch R., Prolla T.A. Gene expression profile of aging and its retardation by caloric restriction. Science. 285:1999;1390-1393.